The pharmacokinetics of metformin in patients receiving intermittent haemodialysis

The aims of this study were to characterise the population pharmacokinetics of metformin in patients receiving haemodialysis, and to determine the doses that will maintain median metformin plasma concentrations below 5 mg L−1 for a typical individual. Metformin plasma concentrations from 5 patients...

Full description

Saved in:
Bibliographic Details
Published in:British journal of clinical pharmacology 2020-07, Vol.86 (7), p.1430-1443
Main Authors: Sinnappah, Klarissa A., Kuan, Isabelle H.S., Thynne, Tilenka R.J., Doogue, Matthew P., Wright, Daniel F.B.
Format: Article
Language:English
Subjects:
haemodialysis
Humans
Metformin
NONMEM
pharmacokinetics
Renal Dialysis
Short Report
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aims of this study were to characterise the population pharmacokinetics of metformin in patients receiving haemodialysis, and to determine the doses that will maintain median metformin plasma concentrations below 5 mg L−1 for a typical individual. Metformin plasma concentrations from 5 patients receiving thrice weekly intermittent haemodialysis followed by metformin 500 mg postdialysis were fitted to a published pharmacokinetic model. Additional models to describe the dialytic pharmacokinetics of metformin were explored. Doses of 250 and 500 postdialysis were simulated from the model for a typical haemodialysis patient. The published 2‐compartment pharmacokinetic model with an additional parameter to describe haemodialysis clearance provided a reasonable fit to the data. Deterministic simulations from the model for a typical individual suggest that metformin doses of 250–500 mg postdialysis and 250 mg given once daily should maintain median metformin plasma concentrations below 5 mg L−1.
ISSN:0306-5251
1365-2125
1365-2125
DOI:10.1111/bcp.14244